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We thank Professor Legemate for his comments
regarding the paper by Miller et al. but feel we must
respond to his criticism of the ESVS’s and the EJVES’s
decision to accept the paper, respectvely, for presen-
tation and publication. With regard to the ESVS
meeting, each submitted abstract is scored blindly by
up to six people who are either members of the EJVES
Editorial Board or EJVES reviewers with a good ‘track
record’. As Miller’s abstract was scored among the top
35 submissions, it was accepted for oral presentation.
The degree to which an abstract reflects the accom-
panying paper varies as does the skill of those that
write the abstracts. However, I question whether a
more elaborate process, perhaps involving submission
of an extended abstract or the full paper, is actually
feasible, when picking out the approximately the top
10% for presentation. Concerning acceptance for the
journal of papers presented at annual meeting, they
are sent to three reviewers the same as any other paper
submitted for the journal. The explicit critique raised
by Prof. Legemate on the use of historic data and the
lack of details regarding survival data, was also raised
by the reviewers. The paper was accepted upon
revision, as I felt data represented the best available.
Here I would like to emphasise, that the decision of
accepting a paper for the journal, is with the editor
alone.
Neither the board nor the reviewers decide—they
advise.
I thank Prof. Legemate for drawing the attention to
these selection processes and excuse the delayed
response.T.V. Schroeder
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Prof. Legemate1 identifies the use of remote historical
controls, whose characteristics are divergent in several
ways from our population, as a fundamental meth-
odological flaw, which renders our findings ‘both
misleading and meaningless’. We considered the
issues of historicity and match at length before we
submitted the abstract, and we debated this point with
commentators from the audience in Dublin and with
reviewers of the manuscript in the publication process.
We freely admit that the match with our cohort is less
than ideal, but we reiterate our point that the study of
Bickerstaff2 and colleagues represents the best evi-
dence we will ever have about the natural history of
thoracic/thoracoabdominal aortic aneurysm.
Fundamentally, Prof. Legemate’s criticism is about
quality of evidence, and it is based on the generally
accepted evidence-based medicine doctrine that clini-
cal trials represent the ultimate in clinical research
evidence. This is generally true, but is not so in this
case.
Watchful waiting clinical trials in vascular surgery
are different than the kinds of clinical trials that
evidence-based guidelines hold in highest esteem. The
difference is that the natural history of aortic
aneurysms is widely enough understood that equi-
poise is disrupted when aneurysms reach a certain
threshold, and surgical treatment—the treatment
being studied—is extended to patients in the non-
surgical group. That is to say, vascular surgery trials
are never run out to the bitter end (e.g. Lederle3).
Crossover triggers involve aneurysm size and rate of
expansion, which have been shown to increase risk of
rupture, and the crossovers are used for ethical, rather
than scientific, reasons. How have size and rate of
expansion been shown to increase risk? By observa-
tional natural history studies, such as the one we used
for our comparison. Therefore, we have clinical
trials—which reside at the top of the evidence
hierarchy—that have crossover rules based on
‘impure’ observational data. It is a peculiar irony
that, when we compute number needed to treat using
the kind of data that force crossover to surgery in
clinical trials, we are taken to task for not using data
from clinical trials!Eur J Vasc Endovasc Surg Vol 30, September 2005
